Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2023 Fiscal Year
Initiated PORT-2 Phase 1/2 IMP-MEL trial in patients with Melanoma & NSCLC Enrollment ongoing in Phase 1 PRECIOUS-01 study of PORT-3 for the treatment of NY-ESO-1 positive solid tumors WESTPORT, Conn., Nov. 23, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc.…